Cognition Therapeutics, Inc. Deferred Income Tax Liabilities, Net
Cognition Therapeutics, Inc. (CGTX) had Deferred Income Tax Liabilities, Net of $67.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-03-26
- 2025-12-31: Deferred Income Tax Liabilities, Net $67.00K.
- 2024-12-31: Deferred Income Tax Liabilities, Net $110.00K.
- 2023-12-31: Deferred Income Tax Liabilities, Net $147.00K.
- 2022-12-31: Deferred Income Tax Liabilities, Net $178.00K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $67.00K 10-K · filed 2026-03-26 |
| 2024-12-31 | $110.00K 10-K · filed 2026-03-26 |
| 2023-12-31 | $147.00K 10-K · filed 2025-03-20 |
| 2022-12-31 | $178.00K 10-K · filed 2024-03-26 |
| 2021-12-31 | $13.00K 10-K · filed 2023-03-23 |
| 2020-12-31 | $22.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |